First-in-human evaluation of 6-bromo-7-[<sup>11</sup>C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 39060376.
- Also identified by DOI 10.1007/s00259-024-06851-2 and PMC identifier 11527933.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Multidrug resistance-associated protein 1 (MRP1) is a transport protein with a widespread tissue distribution, which has been implicated in the pathophysiology of Alzheimer's and chronic respiratory disease. PET with 6-bromo-7-[<sup>11</sup>C]methylpurine ([<sup>11</sup>C]BMP) has been used to measure MRP1 function in rodents. In this study, [<sup>11</sup>C]BMP was for the first time characterised in humans to assess the function of MRP1 and other MRP subtypes in different tissues. Thirteen healthy volunteers (7 men, 6 women) underwent dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [<sup>11</sup>C]BMP. Three subjects of each sex were scanned a second time to assess reproducibility. Volumes of interest were outlined for MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, kidneys, and liver). From the time-activity curves, the elimination rate constant (k<sub>E</sub>, h<sup>- 1</sup>) was derived as a parameter for tissue MRP function and its test-retest variability (TRTV, %) was calculated. Radiation dosimetry was calculated using the Medical Internal Radiation Dose (MIRD) methodology. Mean k<sub>E</sub> and corresponding TRTV values were: cerebral cortex: 0.055 ± 0.010 h<sup>- 1</sup> (- 4 ± 24%), cerebellum: 0.033 ± 0.009 h<sup>- 1</sup> (1 ± 39%), choroid plexus: 0.292 ± 0.059 h<sup>- 1</sup> (0.1 ± 16%), retina: 0.234 ± 0.045 h<sup>- 1</sup> (30 ± 38%), lungs: 0.875 ± 0.095 h<sup>- 1</sup> (- 3 ± 11%), myocardium: 0.641 ± 0.105 h<sup>- 1</sup> (11 ± 25%), kidneys: 1.378 ± 0.266 h<sup>- 1</sup> (14 ± 16%), and liver: 0.685 ± 0.072 h<sup>- 1</sup> (7 ± 9%). Significant sex differences were found for k<sub>E</sub> in the cerebellum, lungs and kidneys. Effective dose was 4.67 ± 0.18 µSv/MBq for men and 4.55 ± 0.18 µSv/MBq for women. LAFOV PET/CT with [<sup>11</sup>C]BMP potentially allows for simultaneous assessment of MRP function in multiple human tissues. Mean TRTV of k<sub>E</sub> in different tissues was in an acceptable range, except for the retina. The radiation dosimetry of [<sup>11</sup>C]BMP was in the typical range of <sup>11</sup>C-tracers. LAFOV PET/CT holds great potential to assess at a whole-body, multi-tissue level molecular targets relevant for drug disposition in humans. EudraCT 2021-006348-29. Registered 15 December 2021.
Medical subject headings
- ATP-Binding Cassette, Sub-Family C Proteins